Iris Wang

The sheer number of new models tracked by OpenRouter and Artificial Analysis means very little if we don't consider the finite resources needed to actually implement them.
Just because something exists doesn't mean it's accessible or affordable for everyone, especially in sectors with dwindling budgets like healthcare.
We already see this with medical software: hundreds of apps, but how many genuinely save time for a busy practice instead of adding another layer of complexity?
Adding more choices when time and training budgets are scarce can actually make things harder, not easier, as attention is rationed across too many options.
It's like offering 600 types of bandages when all a doctor needs is one reliable, cost-effective option for a common cut.

This huge jump from 63 to 668 models on OpenRouter, while tracked closely, doesn't automatically mean anything tangible for daily practical use. We see endless new options, but the finite budget for actual implementation shrinks if there's no clear benefit.
It's like having a new diagnostic machine that costs a fortune but doesn't actually improve patient outcomes or reduce the burden on our overstretched staff.
We need to see if these models genuinely reduce operational costs or improve efficiency in a way that truly matters, not just more choices in a dwindling resource pool.

The explosion of models on OpenRouter, from 63 to 668, feels less like a direct result of simple tracking and more like a drain on already dwindling attention. Just because we track something, like the number of patients seeking a specific therapy, doesn't mean our tracking is the reason for the increase; it's often market demand or developer pushes that truly drive this kind of rapid growth. We have to be careful not to mistake observation for causation, or we'll end up misallocating our finite resources on metrics instead of actual drivers.

Simply tracking model growth from 63 to 668 doesn't automatically mean that information seamlessly populates a dataset or directly causes this expansion; it implies a finite resource conversion that just isn't there.
It's like recording every patient's fever in a file – that's data, yes, but it doesn't automatically cure them or ensure we have the medicine budget to treat them all.
There are always so many other factors, like the actual system capacity or the dwindling availability of specialists.
The connection between tracking and direct expansion is far too simplistic; it suggests an automatic flow of information into actionable growth, which isn't how things work when resources are so scarce.

It's certainly true that tracking model growth shows more options appearing, but that doesn't mean the tracking itself causes platforms like OpenRouter to expand their offerings.
In practice, merely observing a problem, like rising patient numbers, doesn't create more hospital beds or staff; it just highlights the finite resources.
OpenRouter's leap from 63 to 668 models is likely driven by their own business strategy or market pressures, not just the existence of a report.
We see this constantly with new medications—tracking their development is one thing, but getting them funded and widely available is a completely different, resource-intensive challenge.
Every new addition, whether a model or a medicine, drains attention and liquidity from elsewhere if it doesn't offer a demonstrable, sustainable benefit.

That point about the attendance register is spot on; we're running out of room for empty numbers if they don't mean anything. We just don't have the spare attention for more hype.